Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, presented 17 abstracts at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and online during the first weekend in June. Read the titles below and click on the abstract number to review the data.

Research Results

• Breast Cancer—BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the Oncolytic reovirus pelareorep in combination with paclitaxel and avelumab. Amy S. Clark, MD, MSCE (University of Pennsylvania), is the first author. Oral Abstract 1012, part of the Dr. Bernard Fisher Memorial Annual Clinical Science Symposium
• Breast Cancer—ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis. Nhu Thuy Can, MD (Genomic Health), is the first author, and Sunil S. Badve, MD (Emory University), is the senior author. Abstract 515
• Breast Cancer Screening—Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141). Christiane K. Kuhl, MD (Rheinisch-Westfälische Technische Hochschule Aachen), is the first author. Oral Abstract 10502
• Head and Neck Cancer—Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery followed by pathology-based adjuvant treatment in HPV-associated oropharynx cancer. Robert L. Ferris MD, PhD (Hillman Cancer Center), is the first author. Abstract 6036
• Health Equity—Characterizing medical mistrust in a socio-demographically diverse sample of patients with cancer. Cindy Park, MD (Temple University), is the first author. Abstract 10551
• Health Equity—Modeling genetic testing attitudes in a socio-demographically diverse cohort of patients with cancer: The importance of race/ethnicity and medical mistrust. Michael J. Hall, MD, MSc (Fox Chase Cancer Center), is the first author. Abstract 10562
• Kidney Cancer—Core biopsy accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy. Naomi B. Haas, MD (University of Pennsylvania), is the first author. Abstract 4541
• Melanoma—Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial. Elizabeth I. Buchbinder, MD (Dana-Farber Cancer Institute), is the first author. Abstract 12013
• NCI-MATCH—Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2. Niamh Coleman, PhD, MBBCh, MRCP (MD Anderson Cancer Center), is the first author. Abstract 3108
• Pancreatic NETs—Novel use of alternate response criteria for early prediction of outcomes in pancreatic neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study. Namrata Vijayvergia, MD (Fox Chase Cancer Center), is the first author. Abstract 4133
• Prostate Cancer—Landscape and impact of germline pathogenic variants in metastatic hormone-sensitive prostate cancer: ancillary study of E3805 CHAARTED. Anis Hamid, MBBS (University of Melbourne), is the first author. Abstract 5082
• Prostate Cancer—Patient-reported quality of life (QOL) and survival outcomes: analysis of ECOG-ACRIN E3805 chemo-hormonal androgen ablation randomized trial (CHAARTED) in prostate cancer. Daniel Sentana-Lledo, MD (Beth Israel Deaconess Medical Center), is the first author. Abstract 5014
• Smoking Cessation—Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD). Elyse R. Park, PhD, MPH (Massachusetts General Hospital), is the first author. Abstract 1522

Publication Only

• Bioinformatics—A Lasso Cox score consisting of CTLA4+ regulatory T cells, monocytic myeloid derived suppressor cells, and CXCR3+ CD8+ T cells: association with adjuvant ipilimumab survival outcomes in patients with high-risk melanoma. Alyssa Obermayer (H. Lee Moffitt Cancer Center), is the first author. Abstract e21557

Trials in Progress

• Lung Cancer—ECOG-ACRIN LUNG-MAP S1900E substudy: a phase II study of sotorasib in participants with previously treated stage IV or recurrent KRAS G12C mutant non-squamous non-small cell lung cancer. The study chair is Sukhmani Kaur Padda, MD (Cedars-Sinai Medical Center). Abstract TPS9143
• Mesothelioma—Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma: a phase 3, randomized trial (DREAM3R or PrE0506). Patrick M. Forde, MD (Johns Hopkins University), is the study chair in the United States for this international trial. Abstract TPS8599
• Prostate Cancer—Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191. Neha Vapiwala, MD (University of Pennsylvania), is the study chair. Abstract TPS5118